Emergent Biosolutions (EBS) Issues Q3 Miss
Tweet
Share
E-mailGet Alerts EBS Hot Sheet
Price: $2.00 +7.53%
Revenue Growth %: +12.3%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
MAXN, CSTR, ACU, More
Revenue Growth %: +12.3%
Financial Fact:
Contracts and grants: 31.5M
Today's EPS Names:
MAXN, CSTR, ACU, More
Join SI Premium – FREE
Emergent Biosolutions (NYSE: EBS) reported Q3 EPS of $0.04, $0.06 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $58.8 million versus the consensus estimate of $63.59 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- American Express (AXP) down despite beating Q1 estimates on top and bottom lines
- Procter & Gamble (PG) revenue falls short of expectations, raises full-year earnings guidance
- Schlumberger Ltd. (SLB) Reports In-Line Q1 EPS
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
